Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25 -1.92% 12.75 12.50 13.00 13.00 12.75 13.00 255,772 15:59:35
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.0 -1.5 -0.5 - 48

Eden Research Share Discussion Threads

Showing 9701 to 9722 of 10175 messages
Chat Pages: Latest  395  394  393  392  391  390  389  388  387  386  385  384  Older
DateSubjectAuthorDiscuss
02/11/2020
14:30
Eden has had countless tie-ups and agreements over the years, the majority of which have come to nothing. This is welcome but not a harbinger of progress. To repeat what I and others here have stated ad nauseam: what Eden needs are SALES. Nothing short of a reliable sales stream will drive the share price Unfortunately, I don’t believe that Sean Smith and his crew understand this.
erinvale
02/11/2020
10:52
I for one welcome this tiny ripple from the RNS It gives a much closer relationship with the producers of foods.it should give much more visibility . They should seek to replicate this as I think more producers will look into Eden. Better to get out of the bunker,face the market and be proactive.But they need to do far more if they are ever going to justify their salaries and get this company off the ground
chrischas
02/11/2020
10:46
It's not particularly newsworthy and I think I would have kept it under the radar. Not price sensitive so no RNS necessary. Shows some UK development, but also sows the seeds of jam tomorrow which, in my opinion, with Corteva on the horizon, gives the wrong image for Eden.
investingisatrickygame
02/11/2020
08:36
Such, I suspect, is the weariness and wariness among EDEN investors that today's RNS draws little more than sigh. How's the flea treatment getting on? Lols.
brucie5
31/10/2020
23:18
Brucie5 From the 28th February Placing RNS Eden stated "The Corteva Agreement The Fundraise will allow the Company to capitalise on opportunities arising from its relationship with Corteva Agriscience. Eden signed an exclusive evaluation agreement with Corteva Agriscience, the world's fourth largest agriculture input company, in January 2020. Significantly for Eden, regulatory change led to the withdrawal of one of Corteva Agriscience's key seed treatment in the EU. Initial trials by Corteva Agriscience have shown strong results using Eden's products and formulation technology. Eden's formulation technology has been shown to be stable, environmentally friendly and complies with emerging EU regulations concerning polymers. Further trials will be undertaken under a one-year evaluation agreement and, subject to the results, Corteva Agriscience and Eden will look to sign a distribution agreement for the EU, Russia, Ukraine and Turkey giving Eden the opportunity to capture a significant share of this market. The Directors estimate that, if successful, there is the opportunity to generate up to c. €40 million of revenue for Eden from European geographies alone (current market) from this product." The 'significantly for Eden' statement combined with the 'c. €40 million of revenue for Eden from European Geographies alone' is somewhat pointing us in a direction in my opinion. So, as I see this, there is more than the value figure stated to come from this anticipated agreement from other territories outside the EU and I hope that revenue at some level can/will be immediate to replace one of Corteva's key seed treatments. This is all opinions and views, but I have posted my maths before to account for my share price valuation and it assumes a level of profit and is not taken from the gross revenue number.
investingisatrickygame
31/10/2020
18:17
Once the contract is signed we may even hear who has exclusive distribution rights for the USA/Mexico/ Brazil +++rest of the globe seed treatment deal. Perhaps it will be Sumitomo who did the deal with Dupont back in 2017. hTTps://www.agprofessional.com/article/dupont-collaborates-sumitomo-chemical-seed-treatments We Wait.
supersonico
31/10/2020
15:16
Investing, even the revenues will take time to come through, unless you're talking upfront and milestones. But I think, nevertheless, once the contract is signed, if it is, and I see no reason to doubt that it will be, I would be setting my sights on 100m mcap, or c. 20-30p range. Particularly once we hear about CEDROZ in the US. But short-termist that I am, I'll be satisfied with an early break into the teens on receipt of the right news. ;)
brucie5
31/10/2020
12:04
Brucie, I'm not using gross revenues to make my calculation.
investingisatrickygame
31/10/2020
11:52
Re-reading the Jan 8th announcement. again it appears to me there could be a number of possible out comes with the conclusion of the 12 month trail period. a, yes please we would like to start a comerical partnership..asap b, thanks but we'll think about it and get back to you. c, we need more evaluation time (no up front £ offered) d, we need more time (upfront £££ TBD) e, ????? hTTps://www.corteva.com/resources/media-center/corteva-to-evaluate-use-of-plastic-free-capsules-under-eden-research-plc-agreement.html
33mick
31/10/2020
11:39
Investingisatrickygame31 Oct '20 - 09:26 - 8281 of 8281 Based on the Company's RNS, that deal could be worth €40 million per annum (£35 million) ----------------------------------------------------------------------------- Investing, I think we have to be careful with that figure, don't you? 1. It's revenues, not earnings 2. It's a projection, no doubt based on multiple assumptions, and we all know about Eden's *projections* thus far 3. Following which, would you really care to hazard a timescale to those revenues with a company of Eden's historic record of sloth and disappointment? Forgive me for my cynicism. I have, fwiw, re-entered Eden recently.
brucie5
31/10/2020
09:26
FRACMAN2 Let's assume that 8p is fair value today(personally, I don't think that it is) then fair value will have to be appropriated IF the Corteva deal goes ahead. Based on the Company's RNS, that deal could be worth €40 million per annum (£35 million). On an assumptive P/E of 20 (it could be more), Eden's shares would have to value at around a £1+. Corteva has until December 31st 2020 so not long to wait. So I agree that 8p is ridiculous value at the moment.
investingisatrickygame
30/10/2020
18:34
Based on what we already know and the current level of shares in issue it must be undervalued at 8p!! Do everyone agree? I can’t understand why it didn’t continue to climb. More Waiting.
fracman2
30/10/2020
13:18
We await Cedroz news via EPA. Then news re. Corteva's interest in Sustaine. Hence I presume this holding position & tentative Golden Cross formation. Eden is fully funded in the meantime.
brucie5
30/10/2020
08:09
Correct Super. The underlying problem is that Sean Smith seems to think he is doing a good job and pays scant attention to PR - hence the shambles you identify.
erinvale
29/10/2020
17:31
Investing, They maybe up to date and that is why they are selling . eg TT PR shambles?? eg Cedroz global testing plan that Eden conveniently forgot to tell us about until it suited. eg The missing Molluscicide that returned..we hope. eg The Bayer CAP ..unknown Sensible folk some would say given Eden's terrible all promise and no delivery record.
supersonico
29/10/2020
16:58
What's with the selling?! Are people not up-to-date with news due.
investingisatrickygame
27/10/2020
13:09
If nothing is said before January end and there is no promotion worldwide of Mevalone and Cedroz then its a bleak year next year.
chrischas
27/10/2020
12:48
erinvale, Maybe. I just want an answer on the Corteva deal as RNS'd. An RNS to the positive confirming the deal and sales values with be a tremendous boost to Eden and to shareholders whose faith has/is waning. It will also be a signal to those in the seed market that Eden has a viable technology(ies)to support that part of agriculture and with any luck will help with other companies that Eden is talking with. We have to hear by December end, hopefully we can hear earlier.
investingisatrickygame
27/10/2020
12:24
Investing: You don't say! Eden and its precursors have been at this for quarter of a century and they are still at the bottom of the bucket.
erinvale
27/10/2020
12:15
Patience is a virtue here!
investingisatrickygame
23/10/2020
15:44
Surely you mean.. Encapsulated high potency Management Brain Lubricant
supersonico
23/10/2020
15:31
If the past is anything to go by, Eden will have trialled this lubricant in their new lab - on the office chairs perhaps. They will also have an EU patent and approval for use in Albania, a specialist lubricant consultant (or two), and a slew of distribution agreements with big lubricos worldwide. But, as you say, no sales. This re-inforces the usual Eden management disposition that 'talking' equates to 'action'. I think they need a pot of management brain lubricant to get the enterprise off the ground.
erinvale
Chat Pages: Latest  395  394  393  392  391  390  389  388  387  386  385  384  Older
ADVFN Advertorial
Your Recent History
LSE
EDEN
Eden Resea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210127 20:21:42